Study of BioBridge Collagen Matrix with Vascularized Lymph Node Transfer Surgery for Upper Arm Lymphedema After Breast Cancer
Led by Fibralign Corporation · Updated on 2025-03-11
60
Participants Needed
2
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding Fibraligns BioBridge Collagen Matrix devices to standard vascularized lymph node transfer surgery VLNT can improve treatment outcomes for upper arm lymphedema caused by breast cancer. This study focuses on patients who have developed secondary lymphedema after breast cancer therapy and aims to measure changes in limb swelling and lymphatic function. The BioBridge is a sterile, implantable surgical mesh made from purified porcine collagen designed to support soft tissue during VLNT.
Participants will be randomly assigned to one of two groups one receiving VLNT surgery with the BioBridge implant and the other receiving VLNT surgery alone. The BioBridge device supports the lymphatic tissues during surgery. Both groups will undergo the surgical procedure followed by a 12-month follow-up period. The study includes monitoring using imaging and quality of life assessments to evaluate the treatment effects.
Throughout the study, participants will have measurements of their limb volume taken at the start and 12 months after surgery to assess changes in swelling. Additional evaluations include quality of life surveys LLIS, bioimpedance spectroscopy L-Dex, lymphatic function imaging with indocyanine green fluorescence, and tissue histology. Participants are expected to consistently use compression garments and adhere to self-care recommendations. Safety and treatment outcomes will be monitored throughout the study duration, which lasts at least 12 months post-treatment.
CONDITIONS
Brief Title
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
Research Team
S
Scully Hsu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
VLNT + BioBridge
VLNT only
Current standard care (CDT)
What it is
VLNT surgery plus implantation of BioBridge® Collagen Matrix scaffold during lymph node transplant.
VLNT surgery alone without additional scaffold support.
Complete decongestive therapy is the established non‑surgical standard care for breast cancer‑related upper limb lymphedema.
Role in trial
Investigational surgical arm combining VLNT with BioBridge scaffold.
Active comparator surgical arm with VLNT alone.
Not part of the trial; represents usual non‑surgical management for clinical context.
Primary use
Surgical treatment aiming to reduce limb volume and improve lymphatic drainage using scaffold support.
Surgical treatment aiming to reduce limb volume and improve lymphatic drainage without scaffold.
Non‑surgical management to reduce swelling and maintain limb volume through manual therapy, bandaging, and compression.
How it is given or performed
Undergoes VLNT surgery with implantable collagen scaffold at time of lymph node transfer.
Undergoes VLNT surgery without scaffold implantation.
Performed through manual drainage, compression bandaging, skin care, exercise and educator‑guided protocols.
Evidence status
Effectiveness under investigation; no results posted yet.
Surgical VLNT has demonstrated limb volume reduction in prior surgical series and physiological studies.
CDT is the cornerstone non‑surgical therapy and has established benefit in reducing lymphedema volume.
Important risks
Surgical risks include general anesthesia, infection, donor‑site lymphedema; scaffold‑specific risks not fully established.
Risks of VLNT include general surgical risks, donor‑site lymphedema.
Risks are low but include skin irritation, discomfort from compression and pressure ulcers if poorly fitted.
Important limitations
No clinical outcomes published yet; benefits of scaffold adjunct unknown.
Evidence based on surgical series without scaffold; long‑term outcomes and comparisons lacking.
Requires long‑term patient adherence; does not address underlying lymphatic dysfunction surgically.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
Ages 18 to 75 years inclusive
Breast cancer survivors at least 3 years beyond completion of cancer therapy with no clinical disease
Eligible for vascularized lymph node transfer surgery
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
Life expectancy greater than 2 years
Acquired upper limb lymphedema secondary to breast cancer treatment
Swelling in one limb not fully reversible by elevation or compression
Stage I-II lymphedema based on International Society of Lymphology staging
Completed full course of complete decongestive therapy (CDT) including compression garments for at least 12 weeks before screening with no changes
Willingness to consistently use compression garments and comply with self-care during the study, except for the first 3 weeks post-surgery
Limb volume difference of at least 10% between affected and unaffected limbs
Evidence of abnormal bioimpedance ratio (L Dex > 10) if feasible
Ability and willingness to comply with all study procedures and sign informed consent
You will not qualify if you...
Edema caused by increased capillary filtration (venous incompetence)
Unable to safely undergo general anesthesia or perioperative care for surgery
Participation in another investigational drug or therapy trial within 1 month before screening or 5 times the drug's half-life
Recent start (within 12 weeks) of complete decongestive physical therapy (CDPT) for lymphedema
Medical conditions causing acute limb edema such as venous thrombosis or heart failure
Conditions causing symptoms overlapping lymphedema such as pain, swelling, or limited motion
History of clotting disorders
Chronic infection in the affected limb
Infection of the lymphedema limb within 1 month prior to screening
Currently receiving chemotherapy or radiation therapy
Current or recent (within 3 years) malignancy except certain treated skin or cervical cancers
Significant or chronic kidney failure or dialysis
Liver dysfunction with elevated enzymes or bilirubin
Low neutrophil count or hemoglobin levels
Body mass index over 35
Known allergy to porcine products
Anaphylaxis to iodine
Pregnancy or nursing
Substance abuse within 6 months prior to screening
Any other condition that prevents full participation as judged by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Up to 3 weeks post-surgery
Participants undergo vascularized lymph node transplant surgery (VLNT) with or without BioBridge Collagen Matrix implantation, followed by immediate post-operative care.
1 surgery visit and weekly follow-up visits during the first 3 weeks
Post-operative Follow-up
Duration - 12 months
Participants are monitored for changes in limb volume, quality of life, lymphatic function, and other measures for up to 12 months after surgery.
Visits at baseline and 12 months after treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating the Safety and Effectiveness of the Dayspring Wearable Compression System for Breast Cancer Related Lymphedema After Lymphatic Surgery
Expanding Access to Microsurgical Care Using the Symani Surgical System
A Real-world Post-market Evaluation in Free Tissue Transfer and Lymphovenous Anastomosis Surgeries
Real-World Observational Registry Tracking Chronic Wounds and Ulcers Across All Ages and Care Settings
Comparing Quality of Life in Adults with Lymphedema Receiving Surgical Versus Non-Surgical Treatment A Prospective Observational Study
Study of a Program to Prevent Lymphedema After Lymph Node Surgery in Women With Breast Cancer
Effectiveness of Adding Reconstructive Lymphatic Surgery to Usual Decongestive Therapy for Treating Upper or Lower Limb Lymphoedema in Adults
Developing a Surgical Treatment Plan for Chronic Lymphedema After Breast Cancer Surgery Using the Basel Lymphedema Protocol
Comparison of Boosted Compression Therapy Versus Standard Care for Treating Lower Limb Chronic Edema
Evaluating the Symani Surgical System for Microsurgical Lymphatic Reconstruction in Adults with Head and Neck Lymphedema
Study of a Novel Portable Non-Pneumatic Active Compression Device for Treating Lymphedema and Phlebolymphedema
Evaluating Effectiveness and Health Costs in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The role of adjunct nanofibrillar collagen scaffold implantation in the surgical management of secondary lymphedema: Review of the literature and summary of initial pilot studies.
Danielle H Rochlin, Suzanne Inchauste, Justin Zelones...